Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
With a market cap of 1.13B, Intellia Therapeutics(NTLA) trades at $9.77. The stock has a price-to-earnings ratio of -2.12.
On 2025-12-04, Intellia Therapeutics(NTLA) stock moved within a range of $8.85 to $9.92. With shares now at $9.77, the stock is trading +10.4% above its intraday low and -1.5% below the session's peak.
Trading activity shows a volume of 5.88M, compared to an average daily volume of 4.5M.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
NTLA News
Jones Trading recently downgraded Intellia Therapeutics from Buy to Hold following a patient death linked to its NTLA-2001 gene-editing treatment and the result...
Image source: The Motley Fool. Friday, November 7, 2025 at 5:46 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — John Leonard Chief Financial...
